Tuesday, July 5, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Magic mushroom compound helps to ‘open up’ depressed people’s brains after use

by Medical Finance
in Coronavirus
New predictive computer program could help detect individuals at high risk of depression
9
SHARES
100
VIEWS
Share on FacebookShare on Twitter

Psilocybin, the psychedelic compound found in magic mushrooms, helps to “open up” depressed people’s brains, even after use, enabling brain regions to talk more freely to one another.

These are the findings of a new analysis of brain scans from close to 60 people receiving treatment for depression, led by Imperial College London’s Centre for Psychedelic Research. The team behind the study believes it may have untangled how psilocybin exerts its therapeutic effects on the brain.

Psilocybin is one of a number of psychedelics being explored as a potential therapy for psychiatric disorders. Several studies have trialed a synthesized form of the drug to treat patients with depression and anxiety, with promising results.

The new results, taken from two combined studies, reveal that people who responded to psilocybin-assisted therapy showed increased brain connectivity not just during their treatment, but up to three weeks afterwards. This “opening up” effect was associated with self-reported improvements in their depression. However, similar changes in brain connectivity were not seen in those treated with a conventional antidepressant (called escitalopram), suggesting the psychedelic works differently in treating depression.

According to the team, the findings, published today in the journal Nature Medicine, are a promising advance for psilocybin therapy, with the effects replicated across two studies. They explain that patterns of brain activity in depression can become rigid and restricted, and that psilocybin could potentially help the brain to break out of this rut in a way that traditional therapies cannot.

The paper’s senior author Professor Robin Carhart-Harris, former Head of the Imperial Centre for Psychedelic Research who is now based at University of California, San Francisco, said: “The effect seen with psilocybin is consistent across two studies, related to people getting better, and was not seen with a conventional antidepressant.

“In previous studies we had seen a similar effect in the brain when people were scanned whilst on a psychedelic, but here we’re seeing it weeks after treatment for depression, which suggests a ‘carry over’ of the acute drug action.”

Initial findings from two studies carried out at Imperial reported a reduction in measures of depression, but the mechanism underpinning how the treatment exerts these effects has been unclear.

In the latest study, a team led by Imperial’s Centre for Psychedelic Research analysed fMRI scans of participants from these two trials, which included almost 60 participants: an open label trial in treatment-resistant depression – where all participants received psilocybin; and a randomised control trial in more general depression that compared psilocybin with the selective serotonin reuptake inhibitor (SSRI) escitalopram. All participants also received talking therapies with registered mental health professionals and brain scans were taken before, and then one day or three weeks after participants received psilocybin therapy.

Both trials found improvements with psilocybin therapy, as measured by improved participant scores on clinical questionnaires. Analysis of the brain scans revealed altered communication or connectivity between brain regions.

More specifically, they found an increase in communication between those brain regions that are more segregated in depressed patients. They found a correlation between this effect and symptom improvement in both trials – while the strength and duration of effect varied between participants, it was strongest in those who reported an improvement in symptoms. The researchers added that while follow-up data is still being analyzed for participants, initial changes in brain activity one day following treatment were a good predictor of whether a person would still show improvement at six months.

We don’t yet know how long the changes in brain activity seen with psilocybin therapy last and we need to do more research to understand this. We do know that some people relapse, and it may be that after a while their brains revert to the rigid patterns of activity we see in depression.”


Professor Robin Carhart-Harris, Senior Author

The authors caution that while these findings are encouraging, previous trials assessing psilocybin for depression took place under controlled, clinical conditions, using a regulated dose formulated in a laboratory, and involved extensive psychological support before, during and after dosing, provided by mental health professionals.

Patients with depression should not attempt to self-medicate with psilocybin, as taking magic mushrooms or psilocybin in the absence of these careful safeguards may not have a positive outcome.

Professor David Nutt, Head of the Imperial Centre for Psychedelic Research, said: “These findings are important because for the first time we find that psilocybin works differently from conventional antidepressants – making the brain more flexible and fluid, and less entrenched in the negative thinking patterns associated with depression. This supports our initial predictions and confirms psilocybin could be a real alternative approach to depression treatments.”

Professor Carhart-Harris said: “One exciting implication of our findings is that we have discovered a fundamental mechanism via which psychedelic therapy works not just for depression – but other mental illnesses, such as anorexia or addiction. We now need to test if this is the case, and if it is, then we have found something important.”

The research was supported by funding from the Alex Mosley Charitable Trust and founding donors of the Imperial Centre for Psychedelic Research. First author Dr Richard Daws, who is now based at King’s College London, was supported by the Imperial College London EPSRC Centre London for Doctoral Training (CDT) in Neurotechnology.

Source:

Journal reference:

Daws, R.E., et al. (2022) Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine. doi.org/10.1038/s41591-022-01744-z.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Oropharyngeal microbiome profiled at admission is predictive of the need for respiratory support among COVID-19 patients. Image Credit: crystal light / Shutterstock.com

Could oropharyngeal microflora predict COVID-19 patients’ need for respiratory support?

by Medical Finance
July 5, 2022
0

In a recent study published on the preprint server medRxiv*, researchers from the United States identify a subset of oropharyngeal...

Surveying communities may be a useful tool for predicting COVID-19 case trajectories

Charts paint a grim picture 2 years into the coronavirus pandemic

by Medical Finance
July 5, 2022
0

The coronavirus pandemic is now stretching into its third year, a grim milestone that calls for another look at the...

Study: Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and signs of neurodegeneration: a prospective cross-sectional study. Image Credit: White Space Illustrations/Shutterstock

Severity-dependent immune mechanisms in the cerebrospinal fluid and plasma of COVID-19 patients

by Medical Finance
July 5, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers determined the immune mechanisms associated with severe neurological manifestations of...

Study: Cognitive Impairment in Convalescent COVID-19 Patients Undergoing Multidisciplinary Rehabilitation: The Association with the Clinical and Functional Status. Image Credit: Yuganov Konstantin/Shutterstock

Reduced cognitive efficacy and cardiovascular changes in patients post-COVID-19 recovery

by Medical Finance
July 5, 2022
0

In a recent study published in Healthcare, researchers evaluated the association between cognitive impairment and clinical-functional variables in the coronavirus...

Study: Comparing Waves of COVID-19 in the US: Scale of response changes over time. Image Credit: Lightspring/Shutterstock

Relationship between the growth rate of subsequent COVID-19 pandemic waves at the county level in the US

by Medical Finance
July 5, 2022
0

A recent study posted to the medRxiv* preprint server compared the different waves of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)...

Study: Comparative pathogenicity of SARS-CoV-2 Omicron and Delta variants in Syrian hamsters mirrors the attenuated clinical outlook of Omicron in COVID-19 irrespective of age. Image Credit: stock_shot/Shutterstock

The relative dynamics of infection with the Delta and Omicron SARS-CoV-2 variants in aged and young Syrian hamsters

by Medical Finance
July 5, 2022
0

In a recent study posted to the bioRxiv* preprint server, researchers demonstrated the relative pathogenicity of severe acute respiratory syndrome coronavirus...

Next Post
Safety of COVID booster doses and obstetric outcomes in pregnancy

Safety of COVID booster doses and obstetric outcomes in pregnancy

Study: Differential Chromatin Accessibility in Peripheral Blood Mononuclear Cells Underlies COVID-19 Disease Severity Prior To Seroconversion. Image Credit: Rost9 / Shutterstock.com

Chromatin accessibility as an early marker of severe COVID-19

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020–21. Image Credit: TonelloPhotography/Shutterstock
    SARS-CoV-2 burden and transmission in one rural and one urban community in South Africa
  • Examining the potential of CXCR4 and CCR5 as therapeutic targets for cancer and HIV therapy
    Potential of CXCR4 and CCR5 as targets for cancer and HIV therapy
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply